Patents by Inventor Bart E. BURGESS

Bart E. BURGESS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240075204
    Abstract: An auto-injector may include a container capable of comprising a medicament; a shuttle coupled to the container and on a horizontal path with a first state and a second state; an energy source configured to release energy to translate the container and to translate the shuttle, preferably the energy source is pressurized fluid from a can; an impediment preventing horizontal movement of the shuttle before activation of the auto-injector; and a needle having a first end configured to extend out of the auto-injector, and a second end configured to extend into the container, wherein the second end of the needle and the container are not in fluid communication with one another before activation of the auto-injector.
    Type: Application
    Filed: June 29, 2023
    Publication date: March 7, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel HALBIG, Bryan GRYGUS, Trevor LANGLEY, Andrew DUMONT, Bart E. BURGESS, Matthew PAUSLEY, Ross KENYON
  • Publication number: 20230105585
    Abstract: An injection device includes a carrier, a needle, a driver coupled to the needle, the driver being slidable relative to the carrier between a retracted configuration and a deployed configuration, a shuttle configured to move the driver between the retracted configuration and the deployed configuration, and a stop configured to move from a first configuration to a second configuration, wherein the stop is configured to maintain the driver in the deployed configuration, and movement of the stop from the first configuration to the second configuration allows the shuttle to move the driver from the deployed configuration to the retracted configuration.
    Type: Application
    Filed: December 8, 2022
    Publication date: April 6, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Bryan C. GRYGUS, Alfred MARINO, Rachel P. ARNOTT, Scott BARTON, Bart E. BURGESS, Richard GILDERSLEEVE, Alexei GORALTCHOUK, Daniel HALBIG, Christopher KANEL, Trevor LANGLEY
  • Publication number: 20230020306
    Abstract: The present disclosure relates to a therapeutic agent delivery device with anti-roll features. In one embodiment, a therapeutic agent delivery device may include a tubular body including a first end portion, a second end portion, and a lumen extending between the first end portion and the second portion. An outer surface of the tubular body includes a first opening in communication with the lumen. The outer surface of the tubular body further may include a ledge extending around a periphery of the first opening, and a portion of the ledge closest to the second end portion of the tubular body may be shaped as an arrowhead. The therapeutic agent delivery device also may include a cap configured to engage the second end portion of the tubular body, wherein the cap may include a central longitudinal axis, a first end having a first cross-sectional dimension, and a second end having a second cross-sectional dimension larger than the first cross-sectional dimension.
    Type: Application
    Filed: September 23, 2022
    Publication date: January 19, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Courtney NICHOLAS, Scott BARTON, Bart E. BURGESS, Alexei GORALTCHOUK
  • Patent number: 11547801
    Abstract: An injection device includes a carrier, a needle, a driver coupled to the needle, the driver being slidable relative to the carrier between a retracted configuration and a deployed configuration, a shuttle configured to move the driver between the retracted configuration and the deployed configuration, and a stop configured to move from a first configuration to a second configuration, wherein the stop is configured to maintain the driver in the deployed configuration, and movement of the stop from the first configuration to the second configuration allows the shuttle to move the driver from the deployed configuration to the retracted configuration.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 10, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Bryan C. Grygus, Alfred Marino, Rachel P. Arnott, Scott Barton, Bart E. Burgess, Richard Gildersleeve, Alexei Goraltchouk, Daniel Halbig, Christopher Kanel, Trevor Langley
  • Publication number: 20220401302
    Abstract: The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
    Type: Application
    Filed: June 29, 2022
    Publication date: December 22, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Rachel Paige ARNOTT, Bart E. BURGESS, Michael CUPICHA, Alexei GORALTCHOUK, Bryan GRYGUS, Mike STELMAH
  • Patent number: 11484654
    Abstract: The present disclosure relates to a therapeutic agent delivery device with anti-roll features. In one embodiment, a therapeutic agent delivery device may include a tubular body including a first end portion, a second end portion, and a lumen extending between the first end portion and the second portion. An outer surface of the tubular body includes a first opening in communication with the lumen. The outer surface of the tubular body further may include a ledge extending around a periphery of the first opening, and a portion of the ledge closest to the second end portion of the tubular body may be shaped as an arrowhead. The therapeutic agent delivery device also may include a cap configured to engage the second end portion of the tubular body, which may include a curved sidewall extending radially outward. The curved sidewall may include a protrusion.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: November 1, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Courtney Nicholas, Scott Barton, Bart E. Burgess, Alexei Goraltchouk
  • Patent number: 11406565
    Abstract: The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 9, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Rachel Paige Arnott, Bart E. Burgess, Michael Cupicha, Alexei Goraltchouk, Bryan Grygus, Mike Stelmah
  • Publication number: 20220203032
    Abstract: An auto-injector may include a container capable of comprising a medicament; a shuttle coupled to the container and on a horizontal path with a first state and a second state; an energy source configured to release energy to translate the container and to translate the shuttle, preferably the energy source is pressurized fluid from a can; an impediment preventing horizontal movement of the shuttle before activation of the auto-injector; and a needle having a first end configured to extend out of the auto-injector, and a second end configured to extend into the container, wherein the second end of the needle and the container are not in fluid communication with one another before activation of the auto-injector.
    Type: Application
    Filed: December 29, 2021
    Publication date: June 30, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel HALBIG, Bryan GRYGUS, Trevor LANGLEY, Andrew DUMONT, Bart E. BURGESS, Matthew PAUSLEY, Ross KENYON
  • Publication number: 20200139050
    Abstract: The present disclosure relates to a therapeutic agent delivery device with anti-roll features. In one embodiment, a therapeutic agent delivery device may include a tubular body including a first end portion, a second end portion, and a lumen extending between the first end portion and the second portion. An outer surface of the tubular body includes a first opening in communication with the lumen. The outer surface of the tubular body further may include a ledge extending around a periphery of the first opening, and a portion of the ledge closest to the second end portion of the tubular body may be shaped as an arrowhead. The therapeutic agent delivery device also may include a cap configured to engage the second end portion of the tubular body, which may include a curved sidewall extending radially outward. The curved sidewall may include a protrusion.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 7, 2020
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Courtney NICHOLAS, Scott BARTON, Bart E. BURGESS, Alexei GORALTCHOUK
  • Publication number: 20190105230
    Abstract: The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Rachel Paige Arnott, Bart E. Burgess, Michael Cupicha, Alexei Goraltchouk, Bryan Grygus, Mike Stelman
  • Patent number: 10182969
    Abstract: The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: January 22, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Rachel Paige Arnott, Bart E. Burgess, Michael Cupicha, Alexei Goraltchouk, Bryan Grygus, Mike Stelmah
  • Publication number: 20160262984
    Abstract: The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Rachel ARNOTT, Bart E. BURGESS, Michael CUPICHA, Alexei GORALTCHOUK, Bryan GRYGUS, Mykhaylo HRYTSAK
  • Patent number: D932006
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 28, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Courtney Nicholas, Scott Barton, Bart E. Burgess, Alexei Goraltchouk, Paige Waechter, Alex Zuyev
  • Patent number: D958973
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: July 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Courtney Nicholas, Scott Barton, Bart E. Burgess, Alexei Goraltchouk, Paige Waechter